Effects of HMGB1 Expression Suppressed by siRNA on Cell Cycle and Proliferation of Human Cervical Cancer Cell Line HeLa

References

1. ↵
   1. Tang D,
   2. Kang R,
   3. Zeh HJ 3rd., et al.

   High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799:131-140.

   OpenUrlCrossRefPubMed
2. ↵
   1. Meng YX,
   2. Chen J,
   3. Lu ZH, et al.

   Effect of S-100A4 on tumorigenesis, progression, and metastasis. Basic & Clinical Medicine 2006; 26: 1383-1388(Chinese).

   OpenUrl
3. ↵
   1. Littlepage LE,
   2. Sternlicht MD,
   3. Rougier N, et al.

   Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010; 70: 2224-2234.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Ozols RF,
   2. Herbst RS,
   3. Colson YL, et al.

   Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2007; 25: 146-162.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Guo SK,
   2. Qiao YH,
   3. Zhao XL.

   Changes of serum protein in patients with cervical cancer after radical hysterectomy and pelvic lymphadenectomy. Zhongliu Fangzhi Yanjiu Zazhi 2006; 13: 1730-1733 (Chinese).

   OpenUrl
6. ↵
   1. Ogilvie GS,
   2. van Niekerk DJ,
   3. Krajden M, et al.

   A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results. BMC Cancer 2010; 10: 111.

   OpenUrlCrossRefPubMed
7. ↵
   1. Bousarghin L,
   2. Touze A,
   3. Gaud G, et al.

   Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther 2009; 8: 357-365.

   OpenUrlAbstract/FREE Full Text
8. ↵
   1. Huang QX,
   2. Wang GB,
   3. Sun NF, et al.

   Inhibitory effects of high mobility group box 1 antisense nucleotide on invasion of human pancreatic cancer cell line PCNA-1. Ai Zheng 2004; 23: 1036-1040 (Chinese).

   OpenUrlPubMed
9. ↵
   1. Moriwaka Y,
   2. Luo Y,
   3. Ohmori H, et al.

   HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 2010; 77: 17-23.

   OpenUrlCrossRefPubMed
10. ↵
    1. Ulloa L,
    2. Messmer D.

    High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006; 17: 189-201.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Müller S,
    2. Ronfani L,
    3. Bianchi ME, et al.

    Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004; 255: 332-343.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Ichim TE,
    2. Li M,
    3. Qian H, et al.

    RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant 2004; 4: 1227-1236.

    OpenUrlCrossRefPubMed
13. ↵
    1. Song DX,
    2. Chen AM,
    3. Guo JF, et al.

    The effect of specific inhibition of HMGB1 gene expression by siRNA on the proliferation of human prostate carcinoma cell line PC-3. Zhongguo Zhongliu Linchuang 2008; 35: 339-343 (Chinese).

    OpenUrl
14. 1. Huang QX,
    2. Sun NF,
    3. Wang GB, et al.

    Expression of HMGB1 protein in human pancreatic carcinoma. Shiyong Zhongliu Zazhi 2004; 19:19-23 (Chinese).

    OpenUrl
15. ↵
    1. Zhu MG,
    2. Zhang X,
    3. Yuan HY, et al.

    Effects of HMGB1 silence by RNA interference on the apoptosis and cell cycle of hepatocarcinoma cells. Zhongguo Mianyixue Zazhi 2007; 7: 634-636 (Chinese).

    OpenUrl
16. 1. Zhang P,
    2. Liu Y,
    3. Wu ZH, et al.

    Effects of high mobility group box-1 silencing upon the invasion and proliferation in human lung cancer cell L9981 by RNA inhibition. Zhonghua Yixue Zazhi 2009; 89: 3156-3159 (Chinese).

    OpenUrl
17. ↵
    1. Gnanasekar M,
    2. Thirugnanam S,
    3. Ramaswamy K.

    Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009; 34: 425-431.

    OpenUrlPubMed
18. ↵
    1. Van Beijnum JR,
    2. Buurman WA,
    3. Griffioen AW.

    Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-99.

    OpenUrlCrossRefPubMedWeb of Science
19. 1. Riuzzi F,
    2. Sorci G,
    3. Donato R.

    RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007; 171: 947-961.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Taguchi A,
    2. Blood DC,
    3. del Toro G, et al.

    Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastases. Nature 2000; 405: 354-360.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. Bahnassy AA,
    2. Zekri AR,
    3. El-Houssini, et al.

    Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol 2004; 4: 22.

    OpenUrlCrossRefPubMed
22. ↵
    1. Stacey D W.

    CyclinD1 serves as cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003; 15: 158-163.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Reisinger H,
    2. Steinfellner W,
    3. Katinger H, et al.

    Serum-free transfection of CHO cells with chemically defined transfection systems and investigation of their potential for transient and stable transfection. Cytotechnology 2009; 60: 115-123.

    OpenUrlPubMed
24. ↵
    1. Hofacker IL,
    2. Tafer H.

    Designing optimal siRNA based on target site accessibility. Methods Mol Biol 2010; 623: 137-154.

    OpenUrlCrossRefPubMed